Helomics is dedicated to improving patient outcomes by utilizing a proprietary set of laboratory platforms and our Product Science as a Service commercialization model to allow physicians to characterize malignant tumors. Our novel molecular and cellular markers and bioinformatics services are designed to support treatment decisions by providing vital information based on the specific biological processes of each individual's cancer.
Helomics' ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile, which includes: ChemoFx®, BioSpeciFx®, GeneFx Colon and Lung. This approach to precision medicine combines tumor of origin information, genomic expression and molecular information specific and clinically relevant to a patient’s cancer, answering a broad range of clinical questions that physicians encounter every day while managing their patient’s care throughout the Continuum of Cancer.
Our philosophy: Patients first, therapies second. Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal. At Helomics™ we believe that each patient is unique, and their cancer treatment should be too. Our in-depth approach to characterizing patients' live and archived cancer cells allows us to create personal tumor profiles that help physicians to individualize treatment options for their patients.
Helomics' ongoing array of multiple products and technologies provide unique clinical value through a Comprehensive Tumor Profile, which includes: ChemoFx®, BioSpeciFx®, GeneFx Colon and Lung. This approach to precision medicine combines tumor of origin information, genomic expression and molecular information specific and clinically relevant to a patient’s cancer, answering a broad range of clinical questions that physicians encounter every day while managing their patient’s care throughout the Continuum of Cancer.
Our philosophy: Patients first, therapies second. Personalized healthcare should be comprehensive, precise, predictive, but most importantly, personal. At Helomics™ we believe that each patient is unique, and their cancer treatment should be too. Our in-depth approach to characterizing patients' live and archived cancer cells allows us to create personal tumor profiles that help physicians to individualize treatment options for their patients.
Location: United States, Pennsylvania, Pittsburgh
Phone: (800) 547-6165
Founded date: 1995
Investors 1
| Date | Name | Website |
| - | Longitude ... | longitudec... |
Mentions in press and media 3
| Date | Title | Description |
| 19.10.2021 | Predictive Oncology : Launches Website Highlighting AI-Powered Cancer Research Advancements | MINNEAPOLIS, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, an oncology and cancer research company using big data and machine learning to improve pharmaceutical development and predictive treatment outcomes, launched a website toda... |
| 18.01.2019 | CEO invests $1.37M in Precision Therapeutics | Precision Therapeutics (NSDQ:AIPT) CEO Carl Schwartz recently boosted his stake in the company by $1.37 million, including a $950,000 loan and the $50,000 purchase of 78,125 shares of the company’s common stock, representing a price of $0.6... |
| 17.01.2015 | The biggest healthtech deals of 2014 | Categories include telemedicine, digital medical devices and personalized medicine This month, in anticipation of Vator hosting its first ever Splash Health event on February 12th, we've been putting the spotlight on the healthtech space. E... |